JP6356218B2 - 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法 - Google Patents

抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法 Download PDF

Info

Publication number
JP6356218B2
JP6356218B2 JP2016507969A JP2016507969A JP6356218B2 JP 6356218 B2 JP6356218 B2 JP 6356218B2 JP 2016507969 A JP2016507969 A JP 2016507969A JP 2016507969 A JP2016507969 A JP 2016507969A JP 6356218 B2 JP6356218 B2 JP 6356218B2
Authority
JP
Japan
Prior art keywords
compound
formula
ethylpyridine
substituent
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016507969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517849A (ja
JP2016517849A5 (https=
Inventor
ヤーチ ジャオ
ヤーチ ジャオ
ジウチェン ワン
ジウチェン ワン
レンラ フー
レンラ フー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xian Libang Pharmaceutical Technology Co Ltd
Original Assignee
Xian Libang Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xian Libang Pharmaceutical Technology Co Ltd filed Critical Xian Libang Pharmaceutical Technology Co Ltd
Publication of JP2016517849A publication Critical patent/JP2016517849A/ja
Publication of JP2016517849A5 publication Critical patent/JP2016517849A5/ja
Application granted granted Critical
Publication of JP6356218B2 publication Critical patent/JP6356218B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016507969A 2013-04-18 2013-04-18 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法 Expired - Fee Related JP6356218B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/074363 WO2014169462A1 (zh) 2013-04-18 2013-04-18 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法

Publications (3)

Publication Number Publication Date
JP2016517849A JP2016517849A (ja) 2016-06-20
JP2016517849A5 JP2016517849A5 (https=) 2017-03-09
JP6356218B2 true JP6356218B2 (ja) 2018-07-11

Family

ID=51730699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507969A Expired - Fee Related JP6356218B2 (ja) 2013-04-18 2013-04-18 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法

Country Status (8)

Country Link
US (1) US20160060288A1 (https=)
EP (1) EP2987799B1 (https=)
JP (1) JP6356218B2 (https=)
KR (1) KR102046415B1 (https=)
CN (1) CN104936971B (https=)
AU (1) AU2013386732B2 (https=)
CA (1) CA2909418A1 (https=)
WO (1) WO2014169462A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5183514A (en) 1991-04-01 1993-02-02 Texaco Chemical Company Process for dissolving or removing rigid polyurethane foam by contacting with 1,2-dimethyl imidazole
DE4218743C2 (de) * 1992-06-04 2001-10-25 Schering Ag Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP2005524630A (ja) * 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
CN100395259C (zh) * 2004-04-28 2008-06-18 江苏豪森药业股份有限公司 甾体类衍生物
US7790910B2 (en) * 2004-07-27 2010-09-07 Sicor Inc. Process for the preparation of 7α-alkylated 19-norsteroids
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
JP5256042B2 (ja) * 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
US9271990B2 (en) * 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations

Also Published As

Publication number Publication date
US20160060288A1 (en) 2016-03-03
EP2987799A4 (en) 2016-10-05
CN104936971B (zh) 2017-10-13
KR20150143842A (ko) 2015-12-23
CA2909418A1 (en) 2014-10-23
EP2987799B1 (en) 2020-04-08
EP2987799A1 (en) 2016-02-24
KR102046415B1 (ko) 2019-12-02
WO2014169462A1 (zh) 2014-10-23
CN104936971A (zh) 2015-09-23
AU2013386732B2 (en) 2018-10-18
JP2016517849A (ja) 2016-06-20
AU2013386732A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
CN112703003B (zh) 孕烷神经类固醇的脂质前药及其用途
WO2011014661A2 (en) Liver x receptor agonists
WO2023207102A1 (en) Lipid nanoparticles
CN103665087A (zh) 一种萜类化合物及其在医药上的应用
CN104684883A (zh) 新型乌索酸衍生物及其制备方法
CN112076200B (zh) 常春藤皂苷元聚乙二醇衍生物的应用
CN121443581A (zh) 用于肌肉特异性递送的可电离脂质
JP6356218B2 (ja) 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
CN110964078B (zh) 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用
CN101899081B (zh) 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物
JP2007517878A (ja) エチニルエストラジオールのジ−ステロイド型プロドラッグ
CN112175037B (zh) 常春藤皂苷元聚乙二醇衍生物及其制备方法
CN117924106B (zh) 可电离脂质化合物
JP4348475B2 (ja) 新規なジテルペン化合物
CN111574582B (zh) 一种雷公藤红素衍生物及其制备方法与应用
WO2023103929A1 (zh) 氟维司群衍生物及其制备方法和医药用途
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
CN121517601B (zh) 基于透明质酸-脂肪酸偶联前药的自组装纳米制剂
WO2014169456A1 (zh) 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
CN116836216A (zh) 氟维司群衍生物及其制备方法和医药用途
CN121517601A (zh) 基于透明质酸-脂肪酸偶联前药的自组装纳米制剂
CN118598807A (zh) 多酚化衍生物前药化合物其在制备乙酸异丁酸蔗糖酯长效缓释原位凝胶中的应用
HK40088772A (en) Ionizable lipid compounds
KR20220164216A (ko) 신규한 에르고스텐올 유도체 및 이의 용도
HK40084022A (en) Lipid prodrugs of neurosteroids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180613

R150 Certificate of patent or registration of utility model

Ref document number: 6356218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees